** Amplia Therapeutics ATX.AX slips as much as 14% to A$0.245, lowest since July 4
** Stock marks biggest intraday pct drop since June 30
** Drug developer announces capital raise of A$27.5 mln ($18 mln) at issue price of A$0.23, representing 19.3% discount to last close
** Says funds will support ACCENT and AMPLICITY trials, support ovarian cancer trials of co's lead drug, narmafotinib (AMP945
** Stock last down 10.5%, trims YTD gains to ~192%
($1 = A$1.5253)
(Reporting by Anjali Singh in Bengaluru)
((anjali.singh2@thomsonreuters.com;))